Foghorn Therapeutics Highlights Recent Clinical and Research Progress and Provides Strategic Objectives for 2023
January 09, 2023 07:00 ET
|
Foghorn Therapeutics, Inc.
- Phase 1 dose escalation study of FHD-286, a BRG1/BRM inhibitor, in metastatic uveal melanoma continues to progress with initial efficacy and safety data expected in the first half of 2023 - Phase 1...
Foghorn Therapeutics Announces New Preclinical Data for FHD-286 in AML to Be Presented at the American Society of Hematology Annual Meeting
December 05, 2022 07:00 ET
|
Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases...
Foghorn Therapeutics to Participate at the Evercore ISI HealthCONx Conference
November 22, 2022 08:00 ET
|
Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that treat serious diseases...
Foghorn Therapeutics to Present at Connective Tissue Oncology Society Annual Meeting
November 14, 2022 07:00 ET
|
Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases...
Foghorn Therapeutics to Present New Preclinical Data for BRG1/BRM Inhibitor FHD-286 in Combination with Anti-PD-1 Antibody at Society for Immunotherapy of Cancer 37th Annual Meeting
November 09, 2022 07:00 ET
|
Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases...
Foghorn Therapeutics Provides Third Quarter 2022 Financial and Corporate Update
November 08, 2022 07:00 ET
|
Foghorn Therapeutics, Inc.
- FHD-286 Phase 1 dose escalation study in metastatic uveal melanoma continues to progress with initial data expected in the first half of 2023 - FHD-609 Phase 1 pharmacodynamic data shows...
Foghorn Therapeutics Appoints Dr. Thomas J. Lynch, Jr. to Its Board of Directors
October 27, 2022 07:00 ET
|
Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that treat serious diseases...
Foghorn Therapeutics Announces New Data Demonstrating BRD9 Degradation in Patient Tumor Biopsies and Discloses New Selective CBP Program
October 26, 2022 07:00 ET
|
Foghorn Therapeutics, Inc.
Initial Phase 1 data of FHD-609 show degradation of BRD9 in on-treatment metastatic tumor synovial sarcoma biopsies New preclinical data demonstrate FHD-609 is highly selective, with no off-target...
Foghorn Therapeutics to Present at Hanson Wade's 5th Annual Targeted Protein Degradation Summit
October 20, 2022 07:00 ET
|
Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases...
Foghorn Therapeutics to Participate in the Bank of America 2022 Precision Oncology Conference
September 27, 2022 08:00 ET
|
Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that treat serious diseases...